- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Torrent Pharma acquires Zyg Pharma
Torrent Pharmaceuticals Ltd completed acquisition of the city-based Zyg Pharma Ltd for an undisclosed amount, the Ahmedabad-based drug major said on Saturday.
In a regulatory filing to the Bombay Stock Exchange (BSE), Torrent said it had on Friday transacted the entire (100 percent) equity stake of Zyg Pharma in accordance with the share purchase agreement signed on May 5.
"Terms and conditions of the agreement have been satisfied and the entire equity was transferred to the company on July 17," Torrent said in its filing.
The Rs.4,200-crore firm said the acquisition was funded through internal accruals.
Encore group's Zyg Pharma is engaged in manufacturing creams, ointments, gels, lotions and solutions.
Promoted by the Merchant family, the 50-year-old Zyg Pharma has also a manufacturing facility at Pithampur near Indore.
"In line with its strategy to diversify into new therapy segments, the acquisition will help Torrent to strengthen its position in niche dermatological segment in the developed markets like the US and Europe," Zyg said in a statement here.
As a flagship company of the Torrent group, the drug maker has plants at Indrad in Gujarat, Baddi in Himachal Pradesh and Sikkim to produce bulk drugs and formulations for domestic and export markets.Torrent Pharmaceuticals operates in more than 50 countries with over 1000 product registrations globally through its 7 fully owned subsidiares
In a regulatory filing to the Bombay Stock Exchange (BSE), Torrent said it had on Friday transacted the entire (100 percent) equity stake of Zyg Pharma in accordance with the share purchase agreement signed on May 5.
"Terms and conditions of the agreement have been satisfied and the entire equity was transferred to the company on July 17," Torrent said in its filing.
The Rs.4,200-crore firm said the acquisition was funded through internal accruals.
Encore group's Zyg Pharma is engaged in manufacturing creams, ointments, gels, lotions and solutions.
Promoted by the Merchant family, the 50-year-old Zyg Pharma has also a manufacturing facility at Pithampur near Indore.
"In line with its strategy to diversify into new therapy segments, the acquisition will help Torrent to strengthen its position in niche dermatological segment in the developed markets like the US and Europe," Zyg said in a statement here.
As a flagship company of the Torrent group, the drug maker has plants at Indrad in Gujarat, Baddi in Himachal Pradesh and Sikkim to produce bulk drugs and formulations for domestic and export markets.Torrent Pharmaceuticals operates in more than 50 countries with over 1000 product registrations globally through its 7 fully owned subsidiares
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751
Next Story